Acura Pharmaceuticals (OTCMKTS:ACUR) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, October 17th.
Shares of ACUR traded down $0.03 during mid-day trading on Wednesday, hitting $0.21. 20,455 shares of the company’s stock were exchanged, compared to its average volume of 6,758. Acura Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $0.87.
Acura Pharmaceuticals (OTCMKTS:ACUR) last posted its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.08 million for the quarter.
Acura Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
Read More: What is Liquidity?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.